Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Nycomed’s Instanyl single-dose nasal spray approved in EU

Nycomed’s Instanyl single-dose nasal spray approved in EU

6th July 2011

Nycomed has been granted European regulatory approval for Instanyl single-dose nasal spray, a treatment for breakthrough pain (BTP) in cancer patients.

The new product will be launched in EU nations in September 2011 and complements the established multi-dose nasal spray offering, which has been available since 2009.

It has been created by Nycomed with the intention of providing cancer patients with a more flexible, patient-friendly and cost-effective treatment option for BTP, which affects 95 percent of all patients with cancer pain.

The European Commission has approved the new single-dose option across all three Instanyl dose strengths – 50 microgrammes, 100 microgrammes and 200 microgrammes.

Guido Oelkers, executive vice-president at Nycomed, said: "Development of the Instanyl single-dose nasal spray further demonstrates Nycomed's commitment to innovation in areas of clear medical need."

Nycomed is soon set to come under new ownership following the announcement in May 2011 that it is being purchased by Japanese pharmaceutical company Takeda.ADNFCR-8000103-ID-800612882-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.